Jennifer E. Klomp

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Adrienne D. Cox · 10 shared papers, 2019–2026 · strength 1.18
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
2. Channing J. Der · 10 shared papers, 2019–2026 · strength 1.18
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
3. Clint A. Stalnecker · 8 shared papers, 2019–2026 · strength 1.00
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
4. Andrew M. Waters · 8 shared papers, 2019–2026 · strength 0.90
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
5. J. Nathaniel Diehl · 8 shared papers, 2019–2026 · strength 0.87
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
6. Bjoern Papke · 8 shared papers, 2019–2026 · strength 0.82
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
7. Kirsten L. Bryant · 7 shared papers, 2019–2025 · strength 0.80
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
8. Craig M. Goodwin · 6 shared papers, 2020–2026 · strength 0.76
   • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
   • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
9. Mariaelena Pierobon · 7 shared papers, 2019–2025 · strength 0.73
   • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
   • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
   • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
10. Priya S. Hibshman · 4 shared papers, 2021–2026 · strength 0.56
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
11. Lee M. Graves · 4 shared papers, 2021–2026 · strength 0.56
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
12. G. Aaron Hobbs · 5 shared papers, 2019–2026 · strength 0.49
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
13. A. Cole Edwards · 3 shared papers, 2021–2026 · strength 0.46
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
14. Emanuel F. Petricoin · 5 shared papers, 2019–2021 · strength 0.41
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
15. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
16. Kristina Drizyte‐Miller · 3 shared papers, 2021–2025 · strength 0.41
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
17. Devon R. Blake · 3 shared papers, 2021–2026 · strength 0.38
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
18. Andrew J. Aguirre · 3 shared papers, 2020–2026 · strength 0.35
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
19. Emanuel F. Petricoin · 2 shared papers, 2023–2025 · strength 0.32
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. DOI 10.1158/0008-5472.can-22-0391↗
20. Naim U. Rashid · 2 shared papers, 2021–2025 · strength 0.29
    • Paper Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. DOI 10.1126/scisignal.adu7145↗
    • Paper The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancr… DOI 10.1016/j.jbc.2021.101335↗
21. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2026.117627↗
    • Paper Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. DOI 10.1016/j.celrep.2021.109291↗
22. Ye S. Lee · 2 shared papers, 2021–2023 · strength 0.27
    • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
23. Cyrus Vaziri · 1 shared paper, 2023 · strength 0.18
    • Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
24. Jonathan M. DeLiberty · 2 shared papers, 2020–2021 · strength 0.17
    • Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
    • Paper Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-1006↗
25. Nina V. Chaika · 2 shared papers, 2019–2020 · strength 0.14
    • Paper Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-020-0947-8↗
    • Paper Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. DOI 10.1038/s41591-019-0368-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.